COVID-19 weakened the U.S. economy than China’s.
The new studies published in the journal Nature would likely in part be a much lower burden on China through COVID-19:
Long-term T-cell immunity stimulated through prior exposure to SARS virus in 2003 (source: Le Bert et al., Singapore).
Not only is the United States less strategically prepared for the arrival of this virus, but its population may be less biologically prepared.
In the absence of a preexposure of herbal immunity to coronaviruses, vaccines that result in lasting T-cell immunity are of interest to national security.
Without naming China, Singapore researchers (Le Bert et al., 2020) recommend that cross-reactivity of T cells with COVID-19 viral epitopes discovered in the other 23 people tested 17 years after the 2003 SARS cure would possibly “explain some of the differences in the rate of infection or pathology observed this pandemic”. To be clear, China was the epicenter of the 2003 SARS outbreak, and although no new COVID-19 deaths have been reported in China since mid-April, COVID-19 is wreaked havoc in the United States, where there were only 33 SARS cases in China. 2003 (source: WHO). Apart from public aptitude measures, the implication is that even without a vaccine, China already enjoys some degree of collective immunity opposed to COVID-19 due to exposure to SARS in 2003 and other coronaviruses (see sarS list of 2003 country-by-country fleas at the end of this article).
In addition to the geopolitical implications, the Singapore team’s findings have implications for vaccine development: reminiscence T-mobiles are vital. This team demonstrated that T-mobiles in some convalescents in any of the epidemics (SARS 2003 and COVID-19) responded to amounts of nucleocapsid protein that are not unusual for any of the viruses, i.e. shared antigens. Part of this reactivity of the T-mobile shared only in the CD4 subpopulation, while in other convalescent ones, the responsiveness to the SHARED NP design on the CD4 and CD8 T mobiles. This is vital for vaccine developers because it indicates that a viral epitope that causes a CD4 reaction would possibly not cause a CD8 reaction. It may also be vital that an herbal infection causes a T-mobile reaction to NP, an internal viral protein that is not sensitive to neutralizing antibodies such as the complex protein. Complex protein is the target of maximum COVID-19-specific vaccines in development.
Clinical efficacy and protection trial of Sinovac ADVID-19 (inactivated) adsorbed vaccine in health professionals (PROFISCOV) – Sinovac (SVA). Unspecified cell-mediated immune profile
Study on the protection and immunogenicity of GX-19, a COVID-19 preventive DNA vaccine in healthy adults – Genexine (095700.KQ). Immune reaction of antigen-specific IFN-T cells
Safety, tolerance and immunogenicity of a COVID-19 coronavirus vaccine in adults over 18 to – Medicago (private). Specific cell mediation immunity Th1 and Th2
Safety and immunogenicity examination of an inactivated SARS-CoV-2 vaccine to save COVID-19 – Chinese Academy of Medical Sciences. Cellular immune responses (CD4, CD8, Th1, Th2, IFN-, TNF, IL-2, IL-6)
Evaluating the Safety, Tolerability and Immunogenicity of bacTRL-Spike Vaccine for Prevention of COVID-19 – Symvivo (private).
COVID-19 DNA vaccine study (AG0301-COVID19) – Angels (AJW. F)
List of countries with maximum SARS instances in 2003 and in the United States: